The purpose of these experiments was to determine whether the activity of the voltage-dependent Ca2" channel was modulated in the same manner in islets of the ob/ob mouse as in islets of homozygous lean mice of the same strain. The effect of agents that are known to alter the concentrations and movements of intracellular Ca2" were investigated in relation to glucose-stimulated insulin secretion and in relation to the effect of forskolin. In islets of obese mice, verapamil and nifedipine both inhibited glucose-induced insulin release, nifedipine being the more potent inhibitor. Forskolin-stimulated secretion was inhibited either not at all (verapamil) or much less (nifedipine) in islets of the ob/ob mouse compared with those of lean mice. At basal glucose concentrations, verapamil initiated insulin secretion in islets of the ob/ob mouse and acted synergistically with forskolin to evoke a secretory activity that was 3-fold greater than that evoked by 20 mM-glucose. Nifedipine also initiated secretion at basal glucose concentrations and acted synergistically with forskolin, but its effect was considerably smaller than that of verapamil. A comparison of the effect of forskolin in the presence of Ca2"-channel blockers and in the absence of Ca2" suggests that, in the obese mouse, the operation of the voltage-dependent Ca2+ channel is impaired.
INTRODUCTION
The process of stimulus-secretion coupling in the pancreatic f-cell is mediated by an increase in cytosolic Ca2" (Hellman, 1985) . Glucose-induced secretion is completely dependent on the presence of extracellular Ca2", which is believed to enter the f-cell mainly through voltage-dependent Ca2" channels (see Wollheim & Sharp, 1981) . Ca2" can also be mobilized from intracellular stores, a source that is believed to be important to the process of insulin release.
Activators of adenylate cyclase augment the concentrations of cyclic AMP in isolated islets and enhance insulin secretion (Sharp, 1979) . Although cyclic AMP enhances the Ca2" response, the mechanism is still poorly understood (Rasmussen, 1986a,b) . It has been proposed that increases in cyclic AMP potentiate secretion by increasing the amount of Ca2" arising from intracellular stores (Rasmussen, 1986a,b) , by enhancing Ca2" influx through the voltage-dependent Ca21 channels (Henquin & Meissner, 1984a,b,c; Eddlestone et al., 1985) and/or (by analogy with cardiac cells) by inducing the phosphorylation of Ca2+-channel proteins, increasing the probability that the channel is opened (Osterrieder et al., 1982; Cachelin et al., 1983; Bean et al., 1984; Brum et al., 1984) . In neural cells, there is also considerable evidence that cyclic AMP-dependent phosphorylation can decrease the conductance of the K+ channel (Ozawa & Sand, 1986 Jones et al., 1986) .
Although direct biochemical evidence for the presence of voltage-dependent Ca2" channels in islets is lacking, their involvement in insulin secretion has been supported by the use of Ca2"-channel blockers of various types. Antagonists of both the phenylalkylamine (class II) type (Devis et al., 1975; Malaisse et al., 1976; Malaisse & Boschero, 1977; Wollheim et al., 1978) and the diphenylalkylamine (class III) type (Malaisse & Boschero, 1977; decrease 4"Ca2" influx and insulin secretion. Moreover, the Ca2" agonists increase Ca2" uptake and insulin secretion (Malaisse-Lagae et al., 1984; Malaisse & Mathias, 1985; Morgan et al., 1985) . The obese mouse is characterized by an exaggerated insulin-secretory response (Dubuc, 1976; Lavine et al., 1977; Dunbar & Walsh, 1980; Ahren & Lundquist, 1982; Dalpe-Scott et al., 1983) . Insulin secretion in these islets is extremely sensitive to low concentrations of forskolin and less dependent on the provision of normal concentrations of extracellular Ca2" than in the islets of lean mice (Black et al., 1986; M. A. Black, H. M. Heick & N. Begin-Heick, unpublished work). The reports indicating abnormal electrical activity and ionic permeabilities in the islets of obese mice of the Norwich colony prompted us to examine the effects of drugs that alter the Ca2"-channel activity on insulin secretion in islets of obese mice. Table 1 . Effect of verapamil on glucose-induced and forskolin-enhanced insulin secretion Groups of three to four islets were preincubated at 3 mM-glucose and incubated at 20 mM-glucose as described under 'Methods'. Where indicated, verapamil or forskolin was added during the incubation period. Insulin secretion is reported as a percentage of the total insulin content of the islets. The data are means+S.E.M. for n = 10-20 observations. The level of significance (P value) of the differences between samples incubated without and with verapamil is indicated by the numbers in parentheses. Forskolin produced a significant effect in each case. Incubation medium. The composition of the KrebsRinger bicarbonate was as described previously (Black et al., 1986 
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RESULTS
Glucose-induced insulin secretion was decreased in the presence of 50 guM-verapamil in the islets of both lean and obese mice. These experiments show that verapamil had a similar effect on glucose-induced insulin secretion in islets of lean and obese mice. In contrast, in the presence of forskolin, 50 ,M-verapamil effectively inhibited secretion (by 72 %) in the islets of lean mice, but had no effect in the islets of obese mice (Table 1) .
Further experiments showed that the inhibitory effect of verapamil on forskolin-enhanced secretion was dosedependent in islets of lean mice, but a typical dose/ response curve was not obtained in the islets of obese mice (see Fig. la ). To determine whether the failure of verapamil to inhibit secretion in the presence of forskolin in the islets of obese mice was related to the ability of forskolin to induce secretion at non-stimulatory glucose concentrations (Black et al., 1986; M. A. Black, H. M. Heick & N. Begin-Heick, unpublished work), the effects of verapamil at basal glucose concentrations were examined (Table 2) . Verapamil (50 #M) had no significant effect on secretion at basal (3 mM) glucose concentrations in islets of lean mice. Surprisingly, under the same conditions verapamil produced a large stimulatory effect in islets of obese mice. Furthermore, forskolin and verapamil acted synergistically to stimulate insulin secretion at basal glucose concentrations in both types of islets, although the magnitude of the effect was much less in the islets of lean (2 x activity with forskolin alone) than those of obese mice (9 x activity with forskolin alone).
Since at basal glucose concentrations 50 gM-verapamil could actually induce secretion as effectively as 20 mMglucose in islets of obese mice and, with forskolin, synergistically increase secretion even further, we examined the effect of different concentrations of verapamil on forskolin-stimulated insulin secretion in islets of obese mice. As shown in Fig. 1(b) , this stimulatory effect occurred at concentrations above 5 tM, and its magnitude was dose-dependent. Since this effect of verapamil was slight in islets of lean mice, it is concluded that the unusual response to verapamil observed in the islets of obese mice was not due to nonspecific interactions, which would be expected to be similar in both types of islets, but to a functional difference in the two types of islets. Because nifedipine is supposed to act on the voltagedependent Ca2" channel at a site different from that of verapamil (Stanfield, 1986) , it was used to study further the secretory abnormalities in islets of obese mice. The purpose of employing this agent was two-fold: first, to study the issue of a decreased requirement for extracellular Ca2l in the islets of obese mice, and secondly, to see if the stimulatory effects of verapamil at 3 mmglucose could be duplicated by a different Ca2l blocker.
The results in Table 3 show that nifedipine inhibited glucose-induced secretion much more efficiently in islets of obese than of lean mice. Therefore, in contrast with verapamil, nifedipine could effectively block the entry of Ca2" through voltage-dependent channels in islets of obese mice, and thus inhibit insulin secretion. In the presence of forskolin, however, nifedipine was much less effective in the islets of obese than of lean mice.
At 3 mM-glucose (Table 4) , nifedipine by itself produced a 3.5-fold stimulation of secretion in the islets of obese mice. Nifedipine acted synergistically with forskolin in enhancing secretion and, like verapamil, the effect was considerably greater in the islets of obese than of lean mice.
The action of the dihydropyridine Ca2"-channel agonist CGP-28392 was examined next (Table 5 ). In islets of both lean and obese mice, this agent enhanced insulin secretion stimulated by 10 mm-and 20 nivglucose. In the islets of lean mice [and in those of rats, as reported by Malaisse & Mathias (1985) ], this compound did not stimulate secretion at 3 mM-glucose. In contrast, at 3 mM-glucose in the islets of obese mice, stimulation occurred which was similar in magnitude to that produced by nifedipine at that concentration of glucose (cf. Table 4), suggesting a similar mechanism.
The effect of trifluoperazine was examined (Table 6 ) in order to see whether or not it could produce effects similar to those of the more specific Ca2"-channel antagonists, verapamil and nifedipine. Like nifedipine, trifluoperazine inhibited glucose-induced and forskolinpotentiated insulin secretion in islets of obese mice, but it had little effect on these processes in the islets of lean mice. At 3 mM-glucose, trifluoperazine stimulated insulin secretion and, like verapamil and nifedipine, it acted synergistically with forskolin in the islets of lean and obese mice.
One of the suggested effects of forskolin on insulin secretion (via cyclic AMP) is to mobilize stored Ca'. The effect of dantrolene was therefore studied. Te results in Table 7 show that, in the islets of obese mice, Table 2 . Effect of verapamil on basal and forskolin-stimulated insulin secretion Islets were preincubated and incubated in a medium containing 3 mM-glucose and verapamil and forskolin as indicated. The data are means+S.E.M. for the numbers of observations given in parentheses; a indicates that the effect of verapamil is significant (P < 0.001), b that the effect of forskolin is significant (P < 0.001 ), and c that the effect of forskolin and verapamil are significant (P < 0.002). 
Vol. 249 (7) 1.6+0.18* (9) 21.2+ 1.08* (7) Table 4 . Effect of nifedipine on basal and forskolin-stimulated insulin secretion Islets were preincubated and incubated in a medium containing 3 mM-glucose with nifedipine and forskolin as indicated. The data are means+S.E.M. for the numbers of observations in parentheses: a indicates that the effect of nifedipine is significant (P < 0.05), that the effect of forskolin is significant (P < 0.001) and c that the combined effects of forskolin and nifedipine are significantly different (P < 0.001) from either alone. Hess et al. (1984) have proposed that the gating of the voltage-dependent Ca2" channel switches between different modes and that the fl-adrenergic agonist iso- Table 6 . Effect of trilluoperazine on insulin release Islets were preincubated at 3 mM-glucose and incubated at either 3 mm-or 20 mM-glucose, without and with 100 ,1M-forskolin and 20 /tM-trifluoperazine (TFP) as indicated. When added, TFP was present during both the preincubation and the incubation periods. The data represent means + S.E.M. for the numbers of observations in parentheses: 8 forskolin significantly stimulated insulin release at a given concentration of glucose; b TFP significantly increased insulin release; C TFP significantly decreased insulin release. The level of significance was P < 0.01 in each case. 
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Forskolin (#M) ... prenaline, acting via cyclic AMP, increases the number of functional channels by recruitment of channels from mode 0 to mode 1. This change in the properties of the channel is believed to be due to a cyclic AMP-induced phosphorylation (Osterrieder et al., 1982; Cachelin et al., 1983; Bean et al., 1984; Brum et al., 1984) . Likewise, it has been shown that cyclic AMP can lead to depolarization of membranes by promoting the phosphorylation of the Ca2l-activated K+ channels (Dunlap, 1985; Choquet et al., 1987; Grega et al., 1987 (Henquin & Meissner, 1984a; Eddlestone et al., 1985) , and the only important action of forskolin in cells is believed to be that on the adenylate cyclase system (Seamon & Daly, 1986 ).
In the presence of a Ca2+-channel blocker, the stimulatory effect of forskolin should be greatly attenuated, because of the decrease in activity of the Ca2+ channel. The effects of verapamil and nifedipine on glucose-induced insulin secretion (Tables 1 and 3) can be explained on that basis. The difference in the effectiveness of the two drugs could be due to the fact that they interact at different sites in the Ca2l channel (Schramm & Toward, 1985; Spedding, 1985; Stanfield, 1986) , have different potencies (cf. Schramm et al., 1983) , or that verapamil interacts at other sites, such as with the Ca2+-activated K+ channel (Lebrun et al., 1981; Henquin et al., 1982) , in addition to the voltage-dependent Ca2l channel.
In islets of lean mice, forskolin-enhanced insulin secretion was effectively blocked by both nifedipine (by 82 %; since they decreased secretion as effectively as did the removal of Ca2". In the obese mice, the removal of Ca2" was considerably more effective than the blockers in decreasing secretion, demonstrating either that the channels themselves are less effectively blocked by the drugs, or that secretion can occur despite a blocked channel. Neither alternative is consistent with a normal process.
The finding that at basal glucose concentrations nifedipine was an effective inducer of insulin secretion in islets of lean and obese mice, whereas verapamil had an even more pronounced effect, but only in islets of obese mice, was surprising. In the absence of glucose, these compounds appeared to be able to act as Ca2" agonists, an effect that has not previously been described in islet tissue. At basal glucose concentrations, the channels should be primarily in the 'closed' state (in mode 1). It is possible that an antagonist interacting with the Ca2" channel in that state is able to switch and stabilize it into mode 2, increasing Ca2" entry and insulin secretion. The dihydropyridine antagonists have been found to behave as agonists under certain conditions (Hess et al., 1984) ; furthermore, there are types of dihydropyridines (CGP-28392, BAY-k8644) that are agonists and increase the probability that the Ca2" channel remains in the 'open' state (Schramm et al., 1983; Erne et al., 1984) . The finding that CGP-28392 enhanced insulin secretion in islets supports the hypothesis that this compound prolongs the effect of glucose and increases Ca2+ influx through the channels, and the finding that CGP-28392 induced secretion at basal glucose concentrations in the islets of the obese mouse is further evidence for a lack of normal control in this animal.
Although the analogy between the dihydropyridine agonists and antagonists may be an adequate explanation for the action of nifedipine, it is unlikely that it could be invoked to explain the strong stimulatory effect of verapamil at basal glucose concentrations in the islets of obese mice. Lebrun et al. (1981) and Henquin et al. (1982) have reported that the phenylalkylamines can decrease K+ permeability directly, theoretically enhancing Ca2" influx and causing a stimulation rather than an inhibition of insulin secretion. If K+ permeability is already decreased in islets of the obese mouse, as reported by Rosario et al. (1985) and Rosario (1985) , exposure to verapamil would decrease it further and cause a stimulation rather than an inhibition of secretion at basal glucose concentrations; on that basis, one would predict that the stimulation would be enhanced even further in the combined presence of verapamil and forskolin, since the increased cyclic AMP concentrations would further decrease K+ permeability and increase the probability of opening of the Ca21 channel. This is indeed what was observed in the islets of obese mice, but to a much lesser extent in the islets of lean mice. Although cyclic AMP concentrations do not rise as high in the islets of obese as of lean mice in response to forskolin (Black et al., 1986; A. Black, H. M. Heick & N. Begin-Heick, unpublished work), the increase in cyclic AMP induced by forskolin may be sufficient to exacerbate an already abnormal process. This explanation provides a reasonable framework to explain the lack of effect of verapamil on glucose-induced secretion enhanced by forskolin in the islets of obese mice, the stimulatory effect of verapamil at basal glucose concentrations, the synergistic effect of the drug with forskolin and the apparent enhanced sensitivity of the insulin-secretory process to Ca2l in the islets of the obese mouse. Direct measurements of intracellular Ca2l concentrations and work with permeabilized islets may help to clarify the mechanisms further.
